Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390037 | 0.79 | MAPT (0.43) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL8355767 | 0.77 | MAPT (0.38) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL13654381 | 0.76 | MAPT (0.41) | MAPTTP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5149643 | 0.74 | MAPT (0.40) | MAPTTP53CES2CES1CYP3A4 | |
| Methoxymethane SCHEMBL28252357 | 0.73 | MAPT (0.50) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL14948516 | 0.73 | MAPT (0.42) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL28297060 | 0.72 | MAPT (0.48) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL4983413 | 0.72 | MAPT (0.48) | MAPTTP53CES2CES1CYP3A4 | |
| SCHEMBL418090 | 0.72 | — | — | |
| SCHEMBL181942 | 0.72 | MAPT (0.48) | MAPTTP53CES2CES1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776040-B1 | 4-PREGENEN-11SS-17-21-TRIOL-3,20-DIONE DERIVATIVES FOR THE TREATMENT OF OCULAR CONDITIONS | ALLERGAN INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20190216726-A1 | Particles, Compositions and Methods for Ophthalmic and/or Other Applications | OXFORD FINANCE LLC | 2019-07-18 | — | — | US | disclosed |
| WO-2018053321-A1 | PARTICLES, COMPOSITIONS, AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | KALA PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20170182062-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170182062-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| CN-104203247-B | The derovatives of 4 pregnene 11SS, 17 21 triols 3,20 for treating eye disorders | 阿勒根公司 | 2017-06-06 | — | — | CN | disclosed |
| US-9433631-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433631-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150057258-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057258-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. | 2015-02-26 | — | — | US | disclosed |
| CN-104203247-A | 4 - pregenen- 11SS - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions | ALLERGAN INC | 2014-12-10 | — | — | CN | disclosed |
| US-8906892-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906892-B2 | 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2776040-A1 | 4 - PREGENEN- 11SS -17- 21-TRIOL-3,20-DIONE DERIVATIVES FOR THE TREATMENT OF OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071009-A1 | 4 - PREGENEN- 11SS - 17 - 21 -TRIOL-3, 20 -DIONE DERIVATIVES FOR THE TREATMENT OF OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071009-A1 | 4 - PREGENEN- 11SS - 17 - 21 -TRIOL-3, 20 -DIONE DERIVATIVES FOR THE TREATMENT OF OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123223-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123223-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123223-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885TP53 4822/4885CES2 3742/4885 |
| US-20190216726-A1 | Particles, Compositions and Methods for Ophthalmic and/or Other Applications | MUC1, RAB5IF, PDE6C | MAPT 2535/4885TP53 1276/4885CES2 2529/4885 |
| US-20170182062-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885TP53 4822/4885CES2 3742/4885 |
| US-20150057258-A1 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, HSD3B1, HSD3B2 | MAPT 2235/4885TP53 4822/4885CES2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.